3m_istock-458291485_wellesenterprises

wellesenterprises / iStockphoto.com

21 June 2017Americas

BIO 2017: Section 101 raises fundamental policy question, says 3M

The perceived problem with 35 USC section 101 is a “fundamental question of national innovation policy”, claimed Kevin Rhodes, vice president and chief IP counsel at multinational conglomerate 3M.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More on this story

Lanham Act: brand owners’ current weapon of choice

11 June 2020 As opportunistic price-gougers look to capitalise on the COVID-19 pandemic, brands such as 3M have turned to trademark law to try and stop them. Brian Michalek and Erin Westbrook of Saul Ewing Arnstein & Lehr report.

BIO 2018: Stop bashing the patent system, says USPTO director

5 June 2018 “It is my firm belief that folks on all sides need to stop relentlessly bashing the [patent] system if they want it to succeed.”

More features

Startup challenges rival over brain monitoring tech at ITC

UKIPO rejects Boehringer’s SPC for horse inhaler

WilmerHale gains partner with ‘deep expertise’

Bayer, Orion take on Indian generic over $117bn drug

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Lord Justice Birss to become chancellor of the High Court